uniQure (NASDAQ:QURE) Stock Price Up 5.2% Following Analyst Upgrade

uniQure (NASDAQ:QURE)’s stock price traded up 5.2% during mid-day trading on Friday after The Goldman Sachs Group raised their price target on the stock from $9.00 to $20.00. The Goldman Sachs Group currently has a neutral rating on the stock. uniQure traded as high as $15.89 and last traded at $15.85. 460,962 shares changed hands during trading, a decline of 72% from the average session volume of 1,640,178 shares. The stock had previously closed at $15.06.

Other research analysts have also recently issued research reports about the company. Royal Bank of Canada increased their target price on uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday. Cantor Fitzgerald lifted their price target on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $20.00 to $52.00 in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of uniQure in a research note on Tuesday. Finally, Leerink Partners boosted their target price on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $32.14.

Insider Activity at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 4.74% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. RTW Investments LP purchased a new position in shares of uniQure during the third quarter valued at approximately $49,000. China Universal Asset Management Co. Ltd. increased its position in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the last quarter. Atria Investments Inc purchased a new position in shares of uniQure in the third quarter worth approximately $53,000. Quarry LP bought a new position in uniQure in the third quarter worth approximately $58,000. Finally, Vanguard Personalized Indexing Management LLC increased its stake in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Stock Up 2.3 %

The company has a 50-day moving average of $6.85 and a two-hundred day moving average of $6.28. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The company has a market capitalization of $750.60 million, a PE ratio of -3.10 and a beta of 0.89.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Sell-side analysts anticipate that uniQure will post -3.81 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.